Skip to main content
Premium Trial:

Request an Annual Quote

New Releases: Jun 17, 2009

Premium

Clarient announced the launch of its new epidermal growth factor receptor mutation test to help physicians select the right treatment for non-small cell lung cancer patients.

The laboratory-developed test analyzes formalin-fixed, paraffin-embedded tissue samples and detects EGFR mutations to help determine which NSCLC patients will respond to tyrosine kinase inhibitor treatments. The RT-PCR assay detects "the most common mutations of the EGFR gene," according to the company.

Test results are available in 10 to 12 days, the company website notes.

Erlotinib (Genentech's Tarceva) and gefitinib (AstraZeneca's Iressa) are two commonly prescribed TKI's in the treatment of NSCLC.

Several other companies market EGFR mutations tests, including Genzyme and DxS.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.